New progress and development trend of surgical treatment for gastric cancer

Xuefei WANG; Peng ZHOU; Zhaoqing TANG

doi:10.19401/j.cnki.1007-3639.2024.03.002

您当前的位置：

首页 >

文章列表页 >

New progress and development trend of surgical treatment for gastric cancer

Specialist' Commentary | 更新时间：2025-12-31

- New progress and development trend of surgical treatment for gastric cancer
- China Oncology Vol. 34, Issue 3, Pages: 250-258(2024)
- 作者机构：
  
  复旦大学附属中山医院胃肠外科，上海 200032
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2024.03.002
  CLC： R735.2
- Received：20 February 2024，
  
  Revised：2024-03-11，
  
  Published：30 March 2024
- 稿件说明：
移动端阅览
Xuefei WANG, Peng ZHOU, Zhaoqing TANG. New progress and development trend of surgical treatment for gastric cancer[J]. China Oncology, 2024, 34(3): 250-258.
DOI：

Xuefei WANG, Peng ZHOU, Zhaoqing TANG. New progress and development trend of surgical treatment for gastric cancer[J]. China Oncology, 2024, 34(3): 250-258. DOI： 10.19401/j.cnki.1007-3639.2024.03.002.

摘要

胃癌严重威胁人类健康，尽管近年来化疗、靶向治疗和免疫治疗等新型药物研发不断取得突破，但根治性手术始终是胃癌诊疗的核心。随着标准胃癌根治手术的成型，以腹腔镜技术为代表的微创外科治疗技术的进步，进展期胃癌围手术期综合治疗模式的确定，以及胃癌精准外科理念的形成和初步实践，胃癌手术治疗取得了巨大进步。个体化和精准化胃癌外科治疗理念深入人心。安全、有效、精准、微创始终是胃癌外科医师需牢牢把握的学科发展的内在规律。为帮助年轻医师更好的成长，本文总结胃癌诊疗的最新进展，并对未来的发展趋势进行展望。

Abstract

Gastric cancer poses a serious threat to the health of people. Despite the continuous breakthroughs in the development of new drugs such as chemotherapy

targeted therapy and immunotherapy in recent years

radical surgery remains the cornerstone in the treatment of gastric cancer. With the establishment of standard gastric cancer surgery

the advancement of minimally invasive surgical techniques represented by laparoscopy

the determination of perioperative comprehensive treatment of advanced gastric cancer and the formation and initial practice of precise surgical concepts for gastric cancer

the progress of surgical treatment for gastric cancer is advancing by leaps and bounds. The concepts of individualized and optimal treatment are gradually taking root. Safety

effectiveness

precision and minimally invasive approaches have always been the inherent laws of discipline development firmly grasped by gastric cancer surgeons. In order to facilitate better growth for young doctors

the author summarized the latest developments in the diagnosis and treatment of gastric cancer and looked ahead to future trend.

关键词

Keywords

references

ZHENG R S , CHEN R , HAN B F , et al . Cancer incidence and mortality in China, 2022 [J ] . Zhonghua Zhong Liu Za Zhi , 2024 , 46 : 221 - 231 .

YANG W J , ZHAO H P , YU Y , et al . Updates on global epidemiology, risk and prognostic factors of gastric cancer [J ] . World J Gastroenterol , 2023 , 29 ( 16 ): 2452 - 2468 . DOI: 10.3748/wjg.v29.i16.2452 http://doi.org/10.3748/wjg.v29.i16.2452 https://www.wjgnet.com/1007-9327/full/v29/i16/2452.htm https://www.wjgnet.com/1007-9327/full/v29/i16/2452.htm

SMYTH E C , NILSSON M , GRABSCH H I , et al . Gastric cancer [J ] . Lancet , 2020 , 396 ( 10251 ): 635 - 648 . DOI: S0140-6736(20)31288-5 http://doi.org/S0140-6736(20)31288-5

SATO H , NOSHIRO H . Report about the present condition of Billroth’s stomach specimens [J ] . Gastric Cancer , 2019 , 22 ( 6 ): 1310 - 1311 . DOI: 10.1007/s10120-019-00987-z http://doi.org/10.1007/s10120-019-00987-z

GHOSSAIN A , GHOSSAIN M A . History of mastectomy before and after Halsted [J ] . J Med Liban , 2009 , 57 ( 2 ): 65 - 71 .

日本胃癌学会 . 胃癌处理规约 [M ] . 10版. 东京 : 金原出版株式会社 , 1979 .

Japanese Gastric Cancer Association . Gastric cancer management protocol [M ] . 10 edition. Tokyo : Kanehara Publishing Co., LTD , 1979 .

CUSCHIERI A , FAYERS P , FIELDING J , et al . Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group [J ] . Lancet , 1996 , 347 ( 9007 ): 995 - 999 . DOI: 10.1016/s0140-6736(96)90144-0 http://doi.org/10.1016/s0140-6736(96)90144-0

BONENKAMP J J , HERMANS J , SASAKO M , et al . Extended lymph-node dissection for gastric cancer [J ] . N Engl J Med , 1999 , 340 ( 12 ): 908 - 914 . DOI: 10.1056/NEJM199903253401202 http://doi.org/10.1056/NEJM199903253401202 http://www.nejm.org/doi/abs/10.1056/NEJM199903253401202 http://www.nejm.org/doi/abs/10.1056/NEJM199903253401202

SONGUN I , PUTTER H , KRANENBARG E M , et al . Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial [J ] . Lancet Oncol , 2010 , 11 ( 5 ): 439 - 449 . DOI: 10.1016/S1470-2045(10)70070-X http://doi.org/10.1016/S1470-2045(10)70070-X

SASAKO M , SANO T , YAMAMOTO S , et al . D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer [J ] . N Engl J Med , 2008 , 359 ( 5 ): 453 - 462 . DOI: 10.1056/NEJMoa0707035 http://doi.org/10.1056/NEJMoa0707035 http://www.nejm.org/doi/abs/10.1056/NEJMoa0707035 http://www.nejm.org/doi/abs/10.1056/NEJMoa0707035

TSUBURAYA A , MIZUSAWA J , TANAKA Y , et al . Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis [J ] . Br J Surg , 2014 , 101 ( 6 ): 653 - 660 . DOI: 10.1002/bjs.9484 http://doi.org/10.1002/bjs.9484

KUROKAWA Y , TAKEUCHI H , DOKI Y , et al . Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study [J ] . Ann Surg , 2021 , 274 ( 1 ): 120 - 127 . DOI: 10.1097/SLA.0000000000003499 http://doi.org/10.1097/SLA.0000000000003499 https://journals.lww.com/10.1097/SLA.0000000000003499 https://journals.lww.com/10.1097/SLA.0000000000003499

徐泽宽 , 李铮 , 徐皓 . 从2023年国际胃癌大会看胃癌外科治疗进展与发展趋势 [J ] . 中国实用外科杂志 , 2023 , 43 ( 9 ): 971 - 974 .

XU Z K , LI Z , XU H . Progress and trends of surgical treatment for gastric cancer from the International Gastric Cancer Congress 2023(IGCC 2023) [J ] . Chin J Pract Surg , 2023 , 43 ( 9 ): 971 - 974 .

KITANO S , ISO Y , MORIYAMA M , et al . Laparoscopy-assisted billroth Ⅰ gastrectomy [J ] . Surg Laparosc Endosc , 1994 , 4 ( 2 ): 146 - 148 .

YOUNG K , MO H , LEE H H , et al . Laproscopic surgery for gastric cancer [M ] //Management of Gastric Cancer. InTech , 2011 .

KIM H H , HAN S U , KIM M C , et al . Effect of laparoscopic distal gastrectomy vs open distal gastrectomy on long-term survival among patients with stage Ⅰ gastric cancer: the KLASS-01 randomized clinical trial [J ] . JAMA Oncol , 2019 , 5 ( 4 ): 506 - 513 . DOI: 10.1001/jamaoncol.2018.6727 http://doi.org/10.1001/jamaoncol.2018.6727 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6727 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.6727

KATAI H , MIZUSAWA J , KATAYAMA H , et al . Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non-inferiority, phase 3 randomised controlled trial [J ] . Lancet Gastroenterol Hepatol , 2020 , 5 ( 2 ): 142 - 151 .

YU J , HUANG C M , SUN Y H , et al . Effect of laparoscopic vs open distal gastrectomy on 3-year disease-free survival in patients with locally advanced gastric cancer: the CLASS-01 randomized clinical trial [J ] . JAMA , 2019 , 321 ( 20 ): 1983 - 1992 . DOI: 10.1001/jama.2019.5359 http://doi.org/10.1001/jama.2019.5359 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.5359 http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2019.5359

HYUNG W J , YANG H K , HAN S U , et al . A feasibility study of laparoscopic total gastrectomy for clinical stage Ⅰ gastric cancer: a prospective multi-center phase Ⅱ clinical trial, KLASS 03 [J ] . Gastric Cancer , 2019 , 22 ( 1 ): 214 - 222 . DOI: 10.1007/s10120-018-0864-4 http://doi.org/10.1007/s10120-018-0864-4

KATAI H , MIZUSAWA J , KATAYAMA H , et al . Single-arm confirmatory trial of laparoscopy-assisted total or proximal gastrectomy with nodal dissection for clinical stage Ⅰ gastric cancer: Japan Clinical Oncology Group study JCOG1401 [J ] . Gastric Cancer , 2019 , 22 ( 5 ): 999 - 1008 . DOI: 10.1007/s10120-019-00929-9 http://doi.org/10.1007/s10120-019-00929-9

LIU F L , HUANG C M , XU Z K , et al . Morbidity and mortality of laparoscopic vs open total gastrectomy for clinical stage Ⅰ gastric cancer: the CLASS02 multicenter randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 10 ): 1590 - 1597 . DOI: 10.1001/jamaoncol.2020.3152 http://doi.org/10.1001/jamaoncol.2020.3152 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769669 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769669

HASHIZUME M , KONISHI K , TSUTSUMI N , et al . A new era of robotic surgery assisted by a computer-enhanced surgical system [J ] . Surgery , 2002 , 131 ( 1 Suppl ): S330-S333.

LI Z Y , ZHOU Y B , LI T Y , et al . Robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: a multicenter cohort study of 5 402 patients in China [J ] . Ann Surg , 2023 , 277 ( 1 ): e87-e95.

OJIMA T , NAKAMURA M , HAYATA K , et al . Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer: a randomized clinical trial [J ] . JAMA Surg , 2021 , 156 ( 10 ): 954 - 963 . DOI: 10.1001/jamasurg.2021.3182 http://doi.org/10.1001/jamasurg.2021.3182 https://jamanetwork.com/journals/jamasurgery/fullarticle/2783555 https://jamanetwork.com/journals/jamasurgery/fullarticle/2783555

ZONG L , ABE M , SETO Y , et al . The challenge of screening for early gastric cancer in China [J ] . Lancet , 2016 , 388 ( 10060 ): 2606.

中国胃肠肿瘤外科联盟 . 中国胃肠肿瘤外科联盟数据报告(2014—2016) [J ] . 中国实用外科杂志 , 2018 , 38 ( 1 ): 90 - 93 . DOI: 10.19538/j.cjps.issn1005-2208.2018.01.20 http://doi.org/10.19538/j.cjps.issn1005-2208.2018.01.20

China Gastrointestinal Cancer Surgery Union . Data report of China Gastrointestinal Cancer Surgery Union (2014-2016) [J ] . Chin J Pract Surg , 2018 , 38 ( 1 ): 90 - 93 .

SASAKO M , SANO T , YAMAMOTO S , et al . Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial [J ] . Lancet Oncol , 2006 , 7 ( 8 ): 644 - 651 . DOI: 10.1016/S1470-2045(06)70766-5 http://doi.org/10.1016/S1470-2045(06)70766-5

SANO T , SASAKO M , MIZUSAWA J , et al . Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma [J ] . Ann Surg , 2017 , 265 ( 2 ): 277 - 283 . DOI: 10.1097/SLA.0000000000001814 http://doi.org/10.1097/SLA.0000000000001814

KUROKAWA Y , DOKI Y , MIZUSAWA J , et al . Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial [J ] . Lancet Gastroenterol Hepatol , 2018 , 3 ( 7 ): 460 - 468 .

SAKURAMOTO S , SASAKO M , YAMAGUCHI T , et al . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine [J ] . N Engl J Med , 2007 , 357 ( 18 ): 1810 - 1820 . DOI: 10.1056/NEJMoa072252 http://doi.org/10.1056/NEJMoa072252 http://www.nejm.org/doi/abs/10.1056/NEJMoa072252 http://www.nejm.org/doi/abs/10.1056/NEJMoa072252

BANG Y J , KIM Y W , YANG H K , et al . Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial [J ] . Lancet , 2012 , 379 ( 9813 ): 315 - 321 . DOI: 10.1016/S0140-6736(11)61873-4 http://doi.org/10.1016/S0140-6736(11)61873-4 https://linkinghub.elsevier.com/retrieve/pii/S0140673611618734 https://linkinghub.elsevier.com/retrieve/pii/S0140673611618734

CUNNINGHAM D , ALLUM W H , STENNING S P , et al . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer [J ] . N Engl J Med , 2006 , 355 ( 1 ): 11 - 20 . DOI: 10.1056/NEJMoa055531 http://doi.org/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531 http://www.nejm.org/doi/abs/10.1056/NEJMoa055531

AL-BATRAN S E , HOMANN N , PAULIGK C , et al . Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J ] . Lancet , 2019 , 393 ( 10184 ): 1948 - 1957 . DOI: 10.1016/S0140-6736(18)32557-1 http://doi.org/10.1016/S0140-6736(18)32557-1 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571 https://linkinghub.elsevier.com/retrieve/pii/S0140673618325571

ZHANG X T , LIANG H , LI Z Y , et al . Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial [J ] . Lancet Oncol , 2021 , 22 ( 8 ): 1081 - 1092 . DOI: 10.1016/S1470-2045(21)00297-7 http://doi.org/10.1016/S1470-2045(21)00297-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002977 https://linkinghub.elsevier.com/retrieve/pii/S1470204521002977

KANG Y K , YOOK J H , PARK Y K , et al . PRODIGY: a phase Ⅲ study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer [J ] . J Clin Oncol , 2021 , 39 ( 26 ): 2903 - 2913 . DOI: 10.1200/JCO.20.02914 http://doi.org/10.1200/JCO.20.02914 https://ascopubs.org/doi/10.1200/JCO.20.02914 https://ascopubs.org/doi/10.1200/JCO.20.02914

BANG Y J , VAN CUTSEM E , FEYEREISLOVA A , et al . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J ] . Lancet , 2010 , 376 ( 9742 ): 687 - 697 . DOI: 10.1016/S0140-6736(10)61121-X http://doi.org/10.1016/S0140-6736(10)61121-X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X https://linkinghub.elsevier.com/retrieve/pii/S014067361061121X

SHAH M A , SHITARA K , AJANI J A , et al . Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial [J ] . Nat Med , 2023 , 29 ( 8 ): 2133 - 2141 . DOI: 10.1038/s41591-023-02465-7 http://doi.org/10.1038/s41591-023-02465-7

HOFHEINZ R D , HEGEWISCH-BECKER S , KUNZMANN V , et al . Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase Ⅱ trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group [J ] . Int J Cancer , 2021 , 149 ( 6 ): 1322 - 1331 . DOI: 10.1002/ijc.v149.6 http://doi.org/10.1002/ijc.v149.6 https://onlinelibrary.wiley.com/toc/10970215/149/6 https://onlinelibrary.wiley.com/toc/10970215/149/6

RIVERA F , IZQUIERDO-MANUEL M , GARCÍA-ALFONSO P , et al . Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase Ⅱ trial [J ] . Eur J Cancer , 2021 , 145 : 158 - 167 . DOI: 10.1016/j.ejca.2020.12.005 http://doi.org/10.1016/j.ejca.2020.12.005 https://linkinghub.elsevier.com/retrieve/pii/S0959804920314179 https://linkinghub.elsevier.com/retrieve/pii/S0959804920314179

JANJIGIAN Y Y , SHITARA K , MOEHLER M , et al . First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial [J ] . Lancet , 2021 , 398 ( 10294 ): 27 - 40 . DOI: 10.1016/S0140-6736(21)00797-2 http://doi.org/10.1016/S0140-6736(21)00797-2

SHITARA K , VAN CUTSEM E , BANG Y J , et al . Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial [J ] . JAMA Oncol , 2020 , 6 ( 10 ): 1571 - 1580 . DOI: 10.1001/jamaoncol.2020.3370 http://doi.org/10.1001/jamaoncol.2020.3370 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769922 https://jamanetwork.com/journals/jamaoncology/fullarticle/2769922

SHITARA K , MOEHLER M H , AJANI J A , et al . Nivolumab (NIVO)+ chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649 [C ] . Chicago: ASCO , 2024 .

XU J M , JIANG H P , PAN Y Y , et al . Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial [J ] . JAMA , 2023 , 330 ( 21 ): 2064 - 2074 . DOI: 10.1001/jama.2023.19918 http://doi.org/10.1001/jama.2023.19918

TERASHIMA M , KANG Y K , KIM Y W , et al . ATTRACTION-5: a phase 3 study of nivolumab plus chemotherapy as postoperative adjuvant treatment for pathological stage Ⅲ (pStage Ⅲ) gastric or gastroesophageal junction (G/GEJ) cancer [J ] . J Clin Oncol , 2023 , 41 ( 16 _suppl): 4000.

SHITARA K , RHA S Y , WYRWICZ L S , et al . Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study [J ] . Lancet Oncol , 2024 , 25 ( 2 ): 212 - 224 . DOI: 10.1016/S1470-2045(23)00541-7 http://doi.org/10.1016/S1470-2045(23)00541-7

JANJIGIAN Y Y , AL-BATRAN S E , WAINBERG Z A , et al . Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study [J ] . J Clin Oncol , 2024 , 42 ( 3_suppl ): LBA246.

JANJIGIAN Y Y , KAWAZOE A , BAI Y X , et al . Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial [J ] . Lancet , 2023 , 402 ( 10418 ): 2197 - 2208 . DOI: 10.1016/S0140-6736(23)02033-0 http://doi.org/10.1016/S0140-6736(23)02033-0

AL-BATRAN S E , HOMANN N , PAULIGK C , et al . Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial [J ] . JAMA Oncol , 2017 , 3 ( 9 ): 1237 - 1244 . DOI: 10.1001/jamaoncol.2017.0515 http://doi.org/10.1001/jamaoncol.2017.0515 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0515 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.0515

LUO H Y , XU G L , LI C F , et al . Real-time artificial intelligence for detection of upper gastrointestinal cancer by endoscopy: a multicentre, case-control, diagnostic study [J ] . Lancet Oncol , 2019 , 20 ( 12 ): 1645 - 1654 . DOI: S1470-2045(19)30637-0 http://doi.org/S1470-2045(19)30637-0

DONG D , FANG M J , TANG L , et al . Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study [J ] . Ann Oncol , 2020 , 31 ( 7 ): 912 - 920 . DOI: S0923-7534(20)39294-2 http://doi.org/S0923-7534(20)39294-2

DONG D , TANG L , LI Z Y , et al . Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer [J ] . Ann Oncol , 2019 , 30 ( 3 ): 431 - 438 . DOI: S0923-7534(19)31081-6 http://doi.org/S0923-7534(19)31081-6

SUNDAR R , BARR KUMARAKULASINGHE N , HUAK CHAN Y , et al . Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase Ⅲ SAMIT trial [J ] . Gut , 2022 , 71 ( 4 ): 676 - 685 . DOI: 10.1136/gutjnl-2021-324060 http://doi.org/10.1136/gutjnl-2021-324060 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-324060 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2021-324060

KATHER J N , PEARSON A T , HALAMA N , et al . Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer [J ] . Nat Med , 2019 , 25 ( 7 ): 1054 - 1056 . DOI: 10.1038/s41591-019-0462-y http://doi.org/10.1038/s41591-019-0462-y

CHEN Q Y , XIE J W , ZHONG Q , et al . Safety and efficacy of indocyanine green tracer-guided lymph node dissection during laparoscopic radical gastrectomy in patients with gastric cancer: a randomized clinical trial [J ] . JAMA Surg , 2020 , 155 ( 4 ): 300 - 311 . DOI: 10.1001/jamasurg.2019.6033 http://doi.org/10.1001/jamasurg.2019.6033 https://jamanetwork.com/journals/jamasurgery/fullarticle/2761887 https://jamanetwork.com/journals/jamasurgery/fullarticle/2761887

CHEN Q Y , ZHONG Q , LIU Z Y , et al . Indocyanine green fluorescence imaging-guided versus conventional laparoscopic lymphadenectomy for gastric cancer: long-term outcomes of a phase 3 randomised clinical trial [J ] . Nat Commun , 2023 , 14 ( 1 ): 7413.

Views

2552

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress and future perspectives of anticancer drug-induced interstitial lung disease/pneumonia in gastric cancer

Progress and prospects of gastric cancer treatment in the 21st century

A study on the immunomicroenvironment characteristics of gastric cancer with neuroendocrine neoplasm and pure gastric cancer

Prospective trial on impact of oral nutritional supplements on elderly patients with nutritional risk after radical surgery for gastric cancer

Discovery and preliminary validation of five early gastric cancer biomarkers, including TAGLN2 and CTSD, based on serum proteomics

Related Author

Xiaoyu GUO

Xiujuan QU

Yonghu XU

Dazhi XU

ZHANG Yi

SUN Haidong

QU Xinglong

ZHAO Bin

Related Institution

Department of Medical Oncology, The First Hospital of China Medical University

Department of Gastric Surgery, Division 1, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Department of Surgical Oncology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Gastrointestinal Surgery, General Surgery, Zhongshan Hospital, Fudan University

AI问答

⁰